02/04/2026
At our core, we believe the future of cancer care begins with earlier detection—and the legacy of Nancy Gardner Sewell continues to move that future closer to reality.
Her vision and commitment to advancing multi-cancer early detection (MCED) have helped catalyze a moment that feels both urgent and full of possibility. Because of leaders like her, the conversation has shifted from if MCED can change outcomes to how we collectively ensure it does so responsibly, equitably, and at scale.
As a company working at the intersection of science, technology, and patient need, we are inspired by the FDA’s evolving engagement with MCED innovation. Clear regulatory pathways, rigorous evidence standards, and ongoing dialogue are essential to translating breakthrough science into tools that truly serve patients and clinicians. Progress in this space is not driven by any single organization—it’s built through collaboration across industry, regulators, researchers, and advocates.
Nancy Gardner Sewell’s legacy is a powerful reminder that meaningful innovation often begins with belief—belief in science, in partnership, and in a future where more cancers are found earlier, when intervention can make the greatest difference.
We are honored to be part of this journey and remain committed to advancing MCED with scientific integrity, transparency, and an unwavering focus on patients. The future of early cancer detection is being shaped now—and we are building it together.
